Why Applied BioMath?
Applied BioMath was founded in 2013 by Dr. John Burke, Dr. Joshua Apgar, and Andrew Sutherland to help revolutionize both the quality and economics of drug invention by applying MID3. Dr. Burke and Dr. Apgar have been leaders in the biological engineering field for decades beginning with their research at Arizona State University, MIT, and Harvard Medical School and continuing with their many roles in top pharmaceutical and biotechnology companies. They, along with Andrew Sutherland, built an innovative, experienced, and passionate team of mathematicians, biologists, engineers, clinical pharmacologists and pharmaceutical industry experts who leverage biology, proprietary technology, high-performance computing (HPC), and decades of industry experience.
Applied BioMath's services are used worldwide by pharmaceutical and biotechnology companies to better understand the desired target product profile for an indication of interest, determine best-in-class properties of a clinical candidate, and identify key differentiators from competitors.
Applied BioMath was awarded a grant for the development of a software platform called Antibody Drug Conjugate (ADC) Workbench to facilitate efficient knowledge discovery and enable rapid knowledge qualification in support of the development of Quantitative Systems Pharmacology Models (QSPM) for ADC projects.
Applied BioMath was awarded a grant for development of a quantitative systems pharmacology model of amyloid beta and tau pathways for clinical trial design and decision making in Alzheimer's Disease and Dementia.
Applied BioMath was awarded $1.5M by the National Institutes of Health (NIH) to enhance the company's proprietary tools and algorithms for analyzing nonclinical data and mechanisms and predicting clinical PK/PD for biologics.
Charitable Giving Program
At Applied BioMath, we believe strongly in giving back to our community. One of our founding principles is to try and make the world a better place. Our products and services help our commercial partners make a better world through development of novel medicines, but our efforts shouldn’t stop there. Embedded in our corporate DNA is the commitment to help others less fortunate than ourselves. As a part of our Corporate Mission, Applied BioMath will partake in an annual Charitable Giving Program, donating a portion of our profits to charities selected by our team. These may be national, international, or local endeavors; the only requirement is that their focus is on helping people.